Apogee Therapeutics (APGE) Competitors $37.06 +0.36 (+0.98%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends APGE vs. RVMD, LNTH, BPMC, BBIO, LEGN, ELAN, CYTK, NUVL, GRFS, and TGTXShould you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Apogee Therapeutics vs. Revolution Medicines Lantheus Blueprint Medicines BridgeBio Pharma Legend Biotech Elanco Animal Health Cytokinetics Nuvalent Grifols TG Therapeutics Revolution Medicines (NASDAQ:RVMD) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment. Is RVMD or APGE more profitable? Apogee Therapeutics' return on equity of -21.81% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Revolution MedicinesN/A -33.67% -30.08% Apogee Therapeutics N/A -21.81%-20.94% Do analysts prefer RVMD or APGE? Revolution Medicines currently has a consensus price target of $66.25, suggesting a potential upside of 64.43%. Apogee Therapeutics has a consensus price target of $89.71, suggesting a potential upside of 142.08%. Given Apogee Therapeutics' higher possible upside, analysts plainly believe Apogee Therapeutics is more favorable than Revolution Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, RVMD or APGE? Revolution Medicines has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Does the media prefer RVMD or APGE? In the previous week, Revolution Medicines had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 6 mentions for Revolution Medicines and 3 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.46 beat Revolution Medicines' score of 0.28 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apogee Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in RVMD or APGE? 94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 8.0% of Revolution Medicines shares are owned by company insiders. Comparatively, 36.1% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor RVMD or APGE? Revolution Medicines received 67 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 75.83% of users gave Revolution Medicines an outperform vote. CompanyUnderperformOutperformRevolution MedicinesOutperform Votes9175.83% Underperform Votes2924.17% Apogee TherapeuticsOutperform Votes24100.00% Underperform VotesNo Votes Which has higher valuation and earnings, RVMD or APGE? Apogee Therapeutics has lower revenue, but higher earnings than Revolution Medicines. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevolution Medicines$11.58M585.28-$436.37M-$3.59-11.22Apogee TherapeuticsN/AN/A-$83.99M-$2.42-15.31 SummaryApogee Therapeutics beats Revolution Medicines on 9 of the 17 factors compared between the two stocks. Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APGE vs. The Competition Export to ExcelMetricApogee TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$2.96B$5.23B$8.96BDividend YieldN/A1.94%5.13%4.04%P/E Ratio-15.3142.7687.2917.29Price / SalesN/A265.171,255.8979.02Price / CashN/A192.9043.8235.97Price / Book4.943.965.324.79Net Income-$83.99M-$41.02M$122.78M$225.07M7 Day Performance-9.72%-1.80%-0.19%1.51%1 Month Performance-17.07%0.47%3.72%4.68%1 Year Performance15.13%-1.73%27.31%20.92% Apogee Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APGEApogee Therapeutics2.3789 of 5 stars$37.06+1.0%$89.71+142.1%+17.3%$1.85BN/A-15.3191RVMDRevolution Medicines4.4707 of 5 stars$42.38+1.4%$66.25+56.3%+50.2%$7.13B$742,000.00-11.80250News CoverageLNTHLantheus4.5484 of 5 stars$95.12-0.8%$131.86+38.6%+65.5%$6.61B$1.50B15.83700Analyst ForecastShort Interest ↑BPMCBlueprint Medicines1.6667 of 5 stars$103.16+18.0%$122.72+19.0%+38.6%$6.55B$434.42M-48.89640Analyst ForecastInsider TradeShort Interest ↑Analyst RevisionGap UpBBIOBridgeBio Pharma4.0906 of 5 stars$33.56+15.4%$48.08+43.3%-8.5%$6.34B$217.77M-13.93400Short Interest ↑High Trading VolumeLEGNLegend Biotech2.5152 of 5 stars$32.24-4.1%$80.62+150.0%-45.5%$5.89B$520.18M-33.941,800Short Interest ↓News CoverageELANElanco Animal Health4.4188 of 5 stars$11.59+1.4%$16.43+41.7%-18.8%$5.73B$4.45B28.989,800CYTKCytokinetics4.3193 of 5 stars$46.38-0.5%$83.64+80.3%-46.6%$5.47B$7.53M-8.62250Analyst ForecastNUVLNuvalent1.7868 of 5 stars$71.99-6.0%$112.36+56.1%+2.7%$5.12BN/A-20.7540Analyst ForecastInsider TradeNews CoverageGRFSGrifols2.0463 of 5 stars$7.25-0.5%N/A+7.2%$4.98B$7.01B5.9426,300Positive NewsGap DownTGTXTG Therapeutics4.4928 of 5 stars$27.82-3.7%$40.67+46.2%+93.1%$4.33B$264.79M-278.17290Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies RVMD Competitors LNTH Competitors BPMC Competitors BBIO Competitors LEGN Competitors ELAN Competitors CYTK Competitors NUVL Competitors GRFS Competitors TGTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APGE) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APGE Stock Alerts